Eufaeria Biosciences
  • Home
  • About Us
  • Pipeline
  • Clinical Trials
  • News/Events
  • Investor Relations
  • Contact Us

News & Events

Upcoming Events

Picture
No current on-site meetings planned for 2020
​

News


​​MADISON, WI – February 19, 2016 – Laura L. Douglass today announced Eufaeria Biosciences, a new biotechnology company that will focus on the development of natural and novel technologies to revitalize overall health and to serve in response to emergency ​and military medicine applications.  Douglass is Chief Executive Officer and a founding investor along with Joseph C. Johnson, Chief Financial Officer.  Christine E. Wood-Tank is appointed as Chief Operating Officer.

Announcing this new investment, Douglass said “this venture will allow us an opportunity to develop new products that are of special interest to us and have the potential to be of significant importance to patients and those in emergency situations”.  Douglass will remain the CEO of Next Generation Clinical Research, a specialized clinical contract research organization founded by Douglass in 1999.  Johnson and Wood-Tank will also continue in their roles at Next Generation as Eufaeria begins new business operations. The company is privately held with the corporate office located in Madison, Wisconsin.

For additional information on this release or general information about Eufaeria Biosciences please contact Christine Wood-Tank, cwoodtank@eufaeriabio.com or visit www.Eufaeriabio.com
COMPANY
Home
About us
​Pipeline
​Clinical Trials

STAY IN TOUCH 
News/Events
​Investor Relations
Contact Us
COPYRIGHT © 2021  ALL RIGHTS RESERVED  |   EUFAERIA BIOSCIENCES   |   TERMS OF USE
  • Home
  • About Us
  • Pipeline
  • Clinical Trials
  • News/Events
  • Investor Relations
  • Contact Us